| 1 |
NCT03300934 |
Completed |
Adolescence and Diabetes:Can an Automated Closed Loop System Improve Control ? |
|
- Device: closed loop glucose control system
|
Interventional
|
Not Applicable |
- Centre Hospitalier du Luxembourg
- University of Cambridge
- Luxembourg Institute of Health
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time spent in glucose target (%) (3.9 - 10 mmol/l)
- Time spent below glucose target (%) (<3.0mmol/l and < 2,5 mmol/l)
- Time spent above glucose target (%) (> 10 mmol/l)
- (and 7 more...)
|
16 |
All |
12 Years to 18 Years (Child, Adult) |
NCT03300934 |
Spidiman |
SPIDIMAN2 |
July 1, 2017 |
July 19, 2018 |
July 19, 2018 |
October 4, 2017 |
July 31, 2018 |
|
- Clinique des Enfants CHluxembourg
Luxembourg, Luxembourg
|
|
| 2 |
NCT03286023 |
Recruiting |
Stereotactic Radiotherapy for Brain Metastases |
|
- Radiation: stereotactic radiotherapy
|
Observational
|
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of tumoral response
- Evaluation of toxicity
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03286023 |
CYM6 Brain metastases CFB 1 |
CKBrainMeta |
October 2014 |
October 2018 |
December 2021 |
September 18, 2017 |
September 18, 2017 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
|
| 3 |
NCT03284151 |
Recruiting |
Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma |
|
|
Observational
|
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Delay between the initial diagnosis and date of salvage treatment
- PSA evaluation
- Birads score evaluation
- (and 3 more...)
|
40 |
Male |
Child, Adult, Older Adult |
NCT03284151 |
CYM6 Prostate CFB2 |
|
January 2015 |
January 2020 |
January 2023 |
September 15, 2017 |
September 15, 2017 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
|
| 4 |
NCT03235557 |
Recruiting |
CyberKnife for Prostate Cancer Patients Aged 70 y or More |
|
|
Observational
|
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Acute and late toxicity (Using the CTCAEv4)
- PSA evaluation
- Digital rectal exam
- (and 3 more...)
|
60 |
Male |
70 Years and older (Older Adult) |
NCT03235557 |
CYM Prostate CFB 1 |
ProRobot |
October 2014 |
October 2018 |
December 2021 |
August 1, 2017 |
August 17, 2018 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
|
| 5 |
NCT03210129 |
Recruiting |
Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients |
- Cancer, Breast
- Cancer of Colon
- Endometrial Cancer
|
- Behavioral: Motivational interviewing
|
Interventional
|
Not Applicable |
- Luxembourg Institute of Health
- Fondation Cancer
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in physical activity behavior
- Body mass index
- Ramped Bruce Protocol test
- (and 3 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03210129 |
DoPH_SMRL_20161208 |
MIPAClux |
July 6, 2017 |
December 31, 2018 |
March 31, 2019 |
July 6, 2017 |
August 29, 2017 |
|
- Luxembourg Institute for Health
Luxembourg, Luxembourg
|
|
| 6 |
NCT03209128 |
Recruiting |
Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala |
- Non Small Cell Lung Cancer
|
- Radiation: Irradiation prophyllactique cérébrale
|
Observational
|
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cognitive function
- Secondary effects according the CTCAE v.4 criteria
- Appearance of brain metastases and their location
- Quality of life (QOL) of patients
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03209128 |
IPC |
IPC |
April 20, 2017 |
December 31, 2019 |
December 31, 2019 |
July 6, 2017 |
August 17, 2018 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
|
| 7 |
NCT03206385 |
Recruiting |
IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume |
|
- Radiation: Radiation treatment
- Radiation: CK Boost Pelvis
|
Observational
|
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Severe toxicity
- Local clinical control rates
- Extra pelvic dissemination rates
- Ability of the multi leaf collimator to better cover the PTVs and to help shortening the delivery times
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03206385 |
CK Boost Pelvis |
Boost_Pelvis |
May 31, 2017 |
December 31, 2023 |
December 31, 2023 |
July 2, 2017 |
August 17, 2018 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
|
| 8 |
NCT03199144 |
Recruiting |
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer |
|
- Drug: Chemotherapy
- Radiation: Stereotactic radiotherapy
- Procedure: Surgery
|
Interventional
|
Phase 2 |
- Centre Francois Baclesse, Luxembourg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- patient overall survival
- positive surgical margins
- toxicity according the CTCAEv4
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03199144 |
Pancreas cancer neoadjuvant |
CKPancreas |
April 20, 2017 |
December 2023 |
December 2023 |
June 26, 2017 |
August 17, 2018 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
|
| 9 |
NCT03115437 |
Recruiting |
Effects of Shoe Cushioning and Body Mass on Injury Risk in Running |
- Running-Related Injury (First-time)
|
- Other: Hard cushioned running shoes
- Other: Soft cushioned running shoes
|
Interventional
|
Not Applicable |
- Luxembourg Institute of Health
- DECATHLON SA
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Running-related injury (First-time)
- Running-related injury (subsequent)
- Step frequency (steps/min)
- (and 12 more...)
|
800 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03115437 |
DOPH_SMRL_20161101 |
RRI_Interv4 |
September 20, 2017 |
July 31, 2018 |
July 31, 2018 |
April 14, 2017 |
March 6, 2018 |
|
- Luxembourg Institute of Health
Luxembourg, Luxembourg
|
|
| 10 |
NCT03103867 |
Completed |
QUality of Control and slEep in Children With diabeteS, Using New Technology |
- Diabetes Mellitus, Type 1
|
- Device: CGM augmented pump with PLGS ,
- Device: Insulin pump with CGM
|
Interventional
|
Not Applicable |
- Centre Hospitalier du Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time in glucose target
- time below glucose target
- Time above glucose target
- (and 3 more...)
|
32 |
All |
6 Years to 14 Years (Child) |
NCT03103867 |
QUEST |
QUEST |
February 23, 2017 |
May 4, 2018 |
July 15, 2018 |
April 6, 2017 |
August 3, 2018 |
|
- Clinique des Enfants CHluxembourg
Luxembourg, Luxembourg
|
|
| 11 |
NCT02931955 |
Completed |
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy |
|
- Other: Blood draw, stool collection.
|
Observational
|
|
- Luxembourg Institute of Health
- Integrated Biobank of Luxembourg
- Centre Hospitalier du Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Predicting the effectiveness of immunotherapy against insect venom and pollens in allergic patients with use of gene expression networks.
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT02931955 |
SYS-T-ACT_01 |
SYS-T-ACT |
August 2016 |
March 2018 |
July 2018 |
October 13, 2016 |
September 5, 2018 |
|
- Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
|
|
| 12 |
NCT01649362 |
Completed
Has Results |
Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants |
- Preterm Infant
- Oral Feeding Performance
|
- Other: prefeeding oral stimulation program
|
Interventional
|
Not Applicable |
- Centre Hospitalier du Luxembourg
- Luxembourg Institute of Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Length of Transition Period
- Length of Hospital Stay
- Breastfeeding Rate at Discharge
|
101 |
All |
Child, Adult, Older Adult |
NCT01649362 |
201105/04 |
|
June 2011 |
November 2012 |
December 2012 |
July 25, 2012 |
March 12, 2014 |
December 18, 2013 |
- Service de néonatologie, Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
|
|
| 13 |
NCT01442805 |
Completed |
Use of Virtual Reality in the Treatment of Flying Phobia |
|
- Behavioral: Virtual Reality Exposure Therapy
- Behavioral: Exposure Therapy through Imagination
|
Interventional
|
Not Applicable |
- Luxembourg Institute of Health
- Centre Hospitalier du Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Flight taken
- Physiological Measures
- Specific Questionnaires
|
36 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01442805 |
20080102 |
|
October 2008 |
September 2011 |
March 2012 |
September 29, 2011 |
March 15, 2017 |
|
- Centre de Recherche Public de la Santé
Strassen, Luxembourg
|
|
| 14 |
NCT01354236 |
Unknown † |
Mental Health Related to School Dropout in Luxembourg |
- Anxiety Disorders
- Mood Disorders
- Eating Disorders
- (and 4 more...)
|
|
Observational
|
|
- Public Research Centre Health, Luxembourg
- Fonds National de la Recherche Scientifique
- Université de Liège
- (and 2 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Prevalence and type of psychiatric disorders
- Family variables (task fulfillment,role performance, communication, affective expression, connectedness, control behaviour, values and standards)
- Socio-economic background (low, medium, high)
|
200 |
All |
16 Years to 25 Years (Child, Adult) |
NCT01354236 |
AFR-CESP-20100403 |
|
January 2011 |
|
|
May 16, 2011 |
May 16, 2011 |
|
- Public Research Centre Health
Luxembourg, Strassen, Luxembourg
|
|
| 15 |
NCT01146132 |
Completed |
Nutrition and Physical Activity in Patients With Cerebrovascular Disease |
- Cerebrovascular Disorders
|
- Dietary Supplement: Conventional diet +/- wine
- Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine
|
Interventional
|
Not Applicable |
- Manon Gantenbein
- Centre Hospitalier du Luxembourg
- Public Research Centre Health, Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
|
- Differences in mean systolic blood pressure in the two diet/sport arms
- Effects on cerebrovascular health profile
- Assessment of genetic marker and/or genetic modifications.
|
119 |
All |
30 Years and older (Adult, Older Adult) |
NCT01146132 |
CRP-Santé |
ALVINA |
June 2009 |
December 2011 |
December 2011 |
June 17, 2010 |
October 5, 2012 |
|
- CHL
Luxembourg, Luxembourg
|
|
| 16 |
NCT00195338 |
Completed
Has Results |
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Percentage of Participants With Completion of Study Treatment
- Change From Baseline in Number of Joints With Active Synovitis at Months 6, 12, 18, 30, 42, 54 and 66
- (and 2 more...)
|
25 |
All |
17 Years and older (Child, Adult, Older Adult) |
NCT00195338 |
0881-101343 |
|
May 2004 |
December 2010 |
December 2010 |
September 19, 2005 |
January 23, 2012 |
January 23, 2012 |
- Pfizer Investigational Site
Luxembourg, Luxembourg
|
|
| 17 |
NCT02099409 |
Completed |
Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg |
|
|
Interventional
|
Not Applicable |
- Centre Hospitalier du Luxembourg
- University of Cambridge
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time spent in normal glucose range ( mg/dl)
- glucose variability ( excursions in mg/dl)
- Time spent in low glucose range (< 60 mg/dl)
- (and 2 more...)
|
15 |
All |
6 Years to 12 Years (Child) |
NCT02099409 |
SPIDLUX 4 |
|
January 2014 |
August 2014 |
August 2014 |
March 28, 2014 |
September 16, 2014 |
|
- DECCP Clinique Pédiatrique de Luxembourg/CHL
Luxembourg, Luxembourg - DECCP Pediatric Clinic , CHLuxembourg
Luxembourg, Luxembourg
|
|
| 18 |
NCT01147562 |
Recruiting |
Biomarker Discovery and Validation in Lung Cancer |
|
- Procedure: Collection of biospecimen
|
Interventional
|
Not Applicable |
- Dr. Guy Berchem
- Integrated Biobank of Luxembourg
- Centre Hospitalier du Luxembourg
- Public Research Centre Health, Luxembourg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Discover and validate molecular biomarkers for lung cancer
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT01147562 |
IBBL0001 |
LCS |
October 2009 |
July 2017 |
October 2020 |
June 22, 2010 |
January 19, 2017 |
|
- Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg - Clinique Sainte Thérèse (Zithaklinik)
Luxembourg, Luxembourg
|
|
| 19 |
NCT00775736 |
Completed |
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin |
- Diabetes
- Diabetes Mellitus, Type 2
|
- Drug: biphasic insulin aspart 30
- Drug: biphasic insulin aspart 50
- Drug: biphasic insulin aspart 70
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The number of serious adverse drug reactions, including major hypoglycaemic episodes, reported during the study period.
- Number of all hypoglycaemic episodes.
- Number of all adverse drug reactions.
- (and 3 more...)
|
611 |
All |
Child, Adult, Older Adult |
NCT00775736 |
BIASP-3665 |
Mix2Mix |
October 2008 |
January 2011 |
January 2011 |
October 20, 2008 |
January 11, 2017 |
|
- Novo Nordisk Investigational Site
Brussels, Belgium - Novo Nordisk Investigational Site
Luxembourg, Luxembourg
|
|
| 20 |
NCT00709917 |
Completed |
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes |
- Diabetes
- Diabetes Mellitus, Type 2
|
|
Observational
|
|
|
Industry |
- Time Perspective: Prospective
|
- Safety (number of hypoglycaemic incidents)
- HbA1C
- safety
- (and 3 more...)
|
2171 |
All |
18 Years and older (Adult, Older Adult) |
NCT00709917 |
AGEE-1857 |
REPAMET |
March 2007 |
January 2008 |
January 2008 |
July 3, 2008 |
March 3, 2016 |
|
- Brussels, Belgium
- Luxembourg, Luxembourg
|
|
| 21 |
NCT02328898 |
Recruiting |
Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent |
- Stable Angina Pectoris
- Acute Coronary Syndrome
|
- Device: Cre8 Stent
- Device: Resolute Integrity stent
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Target Lesion Failure (TLF)
- Net Adverse Clinical Events (NACE)
- Target lesion failure (TLF)
- (and 3 more...)
|
1532 |
All |
18 Years and older (Adult, Older Adult) |
NCT02328898 |
14-244/M |
|
November 2014 |
September 2018 |
September 2020 |
December 31, 2014 |
April 25, 2018 |
|
- Institute of Cardiac Surgery and Interventional Cardiology
Luxembourg, Luxembourg - Zuyderland Medical Centre
Heerlen, Netherlands - UMC Utrecht
Utrecht, Netherlands
|
|
| 22 |
NCT02525562 |
Active, not recruiting |
Stryker NTX Registry Scorpio NRG (Re-"Energize"), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert |
- Arthroplasty, Replacement, Knee
|
- Device: Triathlon Total Knee System with X3 insert
- Device: Scorpio NRG Total Knee System with X3 insert
- Device: Triathlon PKR System with X3 insert
|
Interventional
|
Not Applicable |
- Stryker European Operations BV
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survivorship of the device
- Investigation of clinical performance and patient outcome with the Knee Society Score (KSS)
- Investigation of clinical performance and patient outcome with the Knee Injury and Osteoarthritis Outcome Score (KOOS) patient questionnaire.
- Investigation of clinical performance and patient outcome with the EuroQuol-5 dimension health questionnaire (EQ-5D) patient questionnaire.
|
224 |
All |
Child, Adult, Older Adult |
NCT02525562 |
K-S-044 |
NTX |
June 2012 |
March 2024 |
March 2024 |
August 17, 2015 |
January 9, 2019 |
|
- Kliniken Dr. Erler gGmbH
Nürnberg, Bayern, Germany - Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg - Worcestersire Acute Hospital NHS Trust, Alexandra Hospital
Redditch, Worcestersire, United Kingdom
|
|
| 23 |
NCT00534261 |
Completed |
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? |
- Relapsing Remitting Multiple Sclerosis
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to evaluate the correlation between the MS Functional Composite Index and two Quality of Life scales (MS Quality of Life 54 and AMS Quality of Life) in patients treated with interferon beta-1a (AVONEX®).
- Reproducibility of Quality of Life scales per language version
- Reliability of the Quality of Life scales per language version
- EDSS score throughout the study
|
284 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00534261 |
BIO-BNL 99-01 |
FLAIR |
November 1999 |
|
February 2004 |
September 24, 2007 |
December 13, 2007 |
|
- Coordinating Research Site
Sijsele-Damme, Belgium - Coordinating Research Site
Esch-Sur-Alzette, Luxembourg - Coordinating Research Site
Glasgow, Scotland, United Kingdom
|
|
| 24 |
NCT00117780 |
Completed |
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes |
- Diabetes
- Diabetes Mellitus, Type 1
|
- Drug: insulin detemir
- Drug: insulin aspart
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean HbA1c
- HbA1c
- Adverse events
- (and 4 more...)
|
520 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00117780 |
NN304-1708
2005-001522-88 |
ADAPT |
June 2005 |
October 2006 |
October 2006 |
July 8, 2005 |
June 2, 2017 |
|
- Novo Nordisk Investigational Site
Aalst, Belgium - Novo Nordisk Investigational Site
Lille, France - Novo Nordisk Investigational Site
Luxembourg, Luxembourg
|
|
| 25 |
NCT00681850 |
Completed |
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- HbA1c, LDL-cholesterol, Systolic Blood Pressure
- Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice
|
4027 |
All |
18 Years and older (Adult, Older Adult) |
NCT00681850 |
D3560L00071 |
Optimise |
March 2008 |
January 2010 |
January 2010 |
May 21, 2008 |
June 2, 2010 |
|
- Research Site
Aalst, Belgium - Research Site
Aarschot, Belgium - Research Site
Alsemberg, Belgium - (and 249 more...)
|
|
| 26 |
NCT01081873 |
Completed
Has Results |
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer |
|
- Drug: leuprolide (Lucrin/Lucrin-Tri-depot)
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit
- Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit
- Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit
- (and 14 more...)
|
2717 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01081873 |
PMOS-BELG-04-001 |
|
June 2004 |
December 2010 |
December 2010 |
March 5, 2010 |
October 31, 2012 |
March 26, 2012 |
- Site Reference ID/Investigator# 31196
Aartselaar, Belgium - Site Reference ID/Investigator# 31237
Afsnee, Belgium - Site Reference ID/Investigator# 31121
Alken, Belgium - (and 132 more...)
|
|
| 27 |
NCT01078558 |
Completed |
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis |
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
|
|
Observational
|
|
- AbbVie (prior sponsor, Abbott)
- Veeda Clinical Research
- AbbVie
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Swollen and tender joint count, C reactive protein, Erythrocyte sedimentation rate, Health assessment questionnaire, Body surface area with psoriasis, numerical rating scale, Bath ankylosing spondylitis disease activity index, concomitant medication
- Safety parameters/ SAE reporting
|
5832 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01078558 |
HUM04-28 |
ProAct |
May 13, 2004 |
January 11, 2018 |
January 11, 2018 |
March 2, 2010 |
January 17, 2018 |
|
- CHC Liege
Liège, Liege, Belgium - Algemeen Stedelijk Ziekenhuis
Aalst, Oost-Vlaanderen, Belgium - Reumacentrum
Aalst, Belgium - (and 115 more...)
|
|
| 28 |
NCT00290264 |
Completed |
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma |
|
- Drug: Budesonide/formoterol
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first severe asthma exacerbation
- Number of severe asthma exacerbations
- Mean use of as-needed medication
- (and 2 more...)
|
1000 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT00290264 |
D5890L00009
Eudract No: 2004-001107-36
SALTO |
|
December 2004 |
|
August 2006 |
February 13, 2006 |
January 24, 2011 |
|
- Research Site
Aalst, Belgium - Research Site
Aartrijke, Belgium - Research Site
Alsemberg, Belgium - (and 207 more...)
|
|
| 29 |
NCT01161173 |
Completed
Has Results |
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer |
- Nonsquamous Nonsmall Cell Neoplasm of Lung
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
- Time to Disease Progression
- Progression-free Survival
- (and 3 more...)
|
347 |
All |
18 Years and older (Adult, Older Adult) |
NCT01161173 |
ML21474 |
TEAM |
April 2008 |
August 2012 |
August 2012 |
July 13, 2010 |
March 28, 2016 |
March 28, 2016 |
- Aalst, Belgium
- Antwerpen, Belgium
- Arlon, Belgium
- (and 34 more...)
|
|
| 30 |
NCT00571649 |
Completed
Has Results |
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Enoxaparin
- Drug: Rivaroxaban placebo
- Drug: Enoxaparin placebo
|
Interventional
|
Phase 3 |
- Bayer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days
- Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
- Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days
- (and 11 more...)
|
8101 |
All |
40 Years and older (Adult, Older Adult) |
NCT00571649 |
12839
2007-004614-14 |
MAGELLAN |
December 2007 |
August 2010 |
November 2010 |
December 12, 2007 |
September 15, 2016 |
June 27, 2012 |
- Birmingham, Alabama, United States
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- (and 673 more...)
|
|
| 31 |
NCT02367040 |
Recruiting |
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) |
|
- Drug: Copanlisib (BAY 80-6946)
- Drug: Placebo
- Drug: Rituximab
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Objective tumor response
- Duration of response (DOR)
- (and 6 more...)
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT02367040 |
17067
2013-003893-29 |
CHRONOS-3 |
August 3, 2015 |
May 31, 2020 |
August 28, 2020 |
February 20, 2015 |
January 10, 2019 |
|
- Little Rock, Arkansas, United States
- Rogers, Arkansas, United States
- Long Beach, California, United States
- (and 307 more...)
|
|
| 32 |
NCT02279654 |
Recruiting |
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Ascertain the Disease Progression to AML (through calculation of product limit estimators and incidence rates) for those with transfusion dependent Low to Intermediate 1 risk MDS del 5 q and have been treated with Revlimid
- Overall Survival for patients with transfusion-dependent low to intermediate 1 risk MDS and isolated del (5q) and who have been treated with Lenalidomide
- Adverse Events
- (and 2 more...)
|
241 |
All |
18 Years and older (Adult, Older Adult) |
NCT02279654 |
CC-5013-MDS-010 |
PASS MDS del5q |
December 17, 2014 |
March 31, 2019 |
March 31, 2023 |
October 31, 2014 |
January 15, 2019 |
|
- AZ Klina
Brasschaat, Belgium - AZ Sint Jan
Brugge, Belgium - Hospital Erasm - 808 Route de lennik
Brussels, Belgium - (and 182 more...)
|
|
| 33 |
NCT02236637 |
Completed |
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care |
|
|
Observational
|
|
- Janssen Pharmaceutica N.V., Belgium
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sequencing of treatment initiation, termination, and duration
- Clinical Benefit
- Medical Resource Utilization
- (and 7 more...)
|
3049 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02236637 |
CR100857
212082PCR4001 |
|
June 14, 2013 |
July 9, 2018 |
July 9, 2018 |
September 10, 2014 |
November 14, 2018 |
|
- Salzburg, Austria
- Vienna, Austria
- Aalst, Belgium
- (and 144 more...)
|
|
| 34 |
NCT01381874 |
Completed
Has Results |
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy |
- Metastatic ER+ Her2- Breast Cancer
- Postmenopausal
|
- Drug: Exemestane
- Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
- Drug: Abiraterone acetate + Prednisone or Prednisolone
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Overall Response Rate (ORR)
- (and 4 more...)
|
297 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01381874 |
CR018286
212082BCA2001
2011-000621-80 |
|
August 24, 2011 |
May 9, 2017 |
August 8, 2018 |
June 27, 2011 |
December 4, 2018 |
July 27, 2018 |
- Muscle Shoals, Alabama, United States
- Fresno, California, United States
- Los Angeles, California, United States
- (and 82 more...)
|
|
| 35 |
NCT00858364 |
Terminated
Has Results |
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy |
- Non-Small Cell Lung Cancer
- Anemia
- Cancer
- Lung Cancer
|
- Drug: Darbepoetin alfa
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Overall Survival (OS)
- Progression-free Survival (PFS)
- Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 5 to End of the Efficacy Treatment Period
- (and 5 more...)
|
2549 |
All |
18 Years and older (Adult, Older Adult) |
NCT00858364 |
20070782
2007-005792-34 |
|
July 17, 2009 |
June 7, 2017 |
June 7, 2017 |
March 9, 2009 |
July 6, 2018 |
July 6, 2018 |
- Research Site
Anniston, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Anchorage, Alaska, United States - (and 629 more...)
|
|
| 36 |
NCT00545909 |
Completed |
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis |
- Postmenopausal Osteoporosis
|
- Drug: ibandronate [Bonviva/Boniva]
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of percentage of patients with >=83% adherence to Bonviva in feedback vs no feedback group
- Patient satisfaction by OPSAT-Q and OPPS.
- Tolerability; SAEs.
|
585 |
Female |
55 Years to 85 Years (Adult, Older Adult) |
NCT00545909 |
ML19913 |
|
March 2006 |
August 2008 |
August 2008 |
October 17, 2007 |
November 2, 2016 |
|
- Bregenz, Austria
- Graz, Austria
- Innsbruck, Austria
- (and 54 more...)
|
|
| 37 |
NCT03247023 |
Recruiting |
Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement |
- Degenerative Arthritis
- Rheumatoid Arthritis
- Traumatic Arthritis
|
- Device: Implantation of Integra Cadence Total Ankle Sysyem
|
Observational
|
|
- Integra LifeSciences Corporation
- Integra LifeSciences Services
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Implant survivorship
- Relative change of Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) - Mobility compared to baseline
- Relative change of Range of Motion (ROM) compared to baseline
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03247023 |
T-CTAS-002 |
|
September 18, 2017 |
September 2021 |
September 2029 |
August 11, 2017 |
February 16, 2018 |
|
- Universitair Ziekenhuis Gent
Gent, Belgium - Foot and Ankle Institute
Woluwe-St-Lambert, Belgium - St. Michael's Hospital
Toronto, Canada - (and 3 more...)
|
|
| 38 |
NCT03780231 |
Recruiting |
Effect of Intense Sport Practice in Athletes With Non-ischemic Scar |
- Athletes With Isolated Non-ischemic LGE With no Underlying "Labelled" Cardiomyopathy
|
|
Observational
|
|
- Rennes University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Occurrence of a major cardiac event
- Morphological end-point
- Functional end-point
- Arrhythmic end-point
|
200 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT03780231 |
35RC18_3026_EISCAR |
EISCAR |
October 5, 2018 |
October 5, 2020 |
October 5, 2025 |
December 19, 2018 |
December 19, 2018 |
|
- Baker IDI Heart and Diabetes Institute
Melbourne, Australia - University Hospital Gasthuisberg
Leuven, Belgium - CHU de Rennes
Rennes, France - (and 3 more...)
|
|
| 39 |
NCT01565967 |
Completed |
Registry AutoLog Lipid Removal and Blood Component Characterization |
|
|
Observational
|
|
- Medtronic Bakken Research Center
- Medtronic Cardiovascular
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- level of reduction of nonemulsified fat
|
199 |
All |
Child, Adult, Older Adult |
NCT01565967 |
AutoLog |
|
December 2011 |
March 2013 |
March 2013 |
March 29, 2012 |
October 29, 2015 |
|
- Azienda Ospedaliera Universitaria Materdomini
Catanzaro, Italy - Vilnius University Hospital Santariskiu Klinikos
Vilnius, Lithuania - Institut national de chirurgie cardiaque et de cardiologie interventionnelle (INCCI)
Luxembourg, Luxembourg - (and 3 more...)
|
|
| 40 |
NCT03386929 |
Recruiting |
Survival Prolongation by Rationale Innovative Genomics |
- Non-small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Cancer Stage IIIB
|
- Drug: Avelumab
- Drug: Axitinib
- Drug: Palbociclib
|
Interventional
|
Phase 1
Phase 2 |
- Worldwide Innovative Networking Association
- ARC Foundation for Cancer Research
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT)
- Incidence of the tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events
- Response Rate (RR)
- (and 6 more...)
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT03386929 |
WIN001
2017-001455-32 |
SPRING |
November 29, 2017 |
December 2021 |
December 2022 |
December 29, 2017 |
August 1, 2018 |
|
- UCSD Moores Cancer Center
La Jolla, California, United States - Avera Cancer Center
Sioux Falls, South Dakota, United States - Centre Léon Bérard
Lyon, France - (and 3 more...)
|
|
| 41 |
NCT01874002 |
Active, not recruiting |
Prospective Registry to Asses the Long-term Safety and Performance of the Combo Stent |
|
|
Observational
|
|
- Robbert J de Winter
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adjudicated Target Lesion Failure
- Individual components of target lesion failure (TLF)
- Adjudicated patient-oriented composite Major Adverse Cardiac Events (MACE)
- (and 4 more...)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01874002 |
W12_186
Version 2.0 |
REMEDEE Reg |
June 2013 |
March 2015 |
March 2019 |
June 10, 2013 |
December 30, 2015 |
|
- Pauls Stradins Clinical University Hospital
Riga, Latvia - Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg - Academic Medical Center - University of Amsterdam
Amsterdam, Netherlands - (and 6 more...)
|
|
| 42 |
NCT02720757 |
Terminated |
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO) |
- Pulmonary Disease, Chronic Obstructive
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes in physical functioning based on Patient questionnaire (PF-10) scores
- Patients' satisfaction with Spiolto Respimat using a Patient Satisfaction Survey
- Patients' general condition using the Physician's Global Evaluation (PGE) scale
|
|
All |
40 Years and older (Adult, Older Adult) |
NCT02720757 |
1237.45 |
|
August 26, 2016 |
December 14, 2017 |
December 14, 2017 |
March 28, 2016 |
November 9, 2018 |
|
- Centre Hospitalier Universitaire de Liège
Liège, Belgium - Multiple Locations, Belgium
- Multiple Locations, Denmark
- (and 4 more...)
|
|
| 43 |
NCT03784027 |
Not yet recruiting
New |
The Artificial Pancreas in Very Young Children With T1D |
|
- Device: CamAPS FX
- Other: Sensor augmented therapy
|
Interventional
|
Not Applicable |
- University of Cambridge
- European Commission
- Cambridge University Hospitals NHS Foundation Trust
- (and 10 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl)
- Time spent above target glucose (10.0 mmol/l) (180 mg/dl)
- HbA1c
- (and 15 more...)
|
72 |
All |
1 Year to 7 Years (Child) |
NCT03784027 |
KidsAP02 |
KidsAP02 |
March 2019 |
June 2020 |
June 2020 |
December 21, 2018 |
December 21, 2018 |
|
- Medical University of Graz Department of Pediatrics and Adolescent Medicine
Graz, Austria - Medical University of Innsbruck Department of Pediatrics I
Innsbruck, Austria - Medical University of Vienna Department of Pediatrics
Wien, Austria - (and 5 more...)
|
|
| 44 |
NCT03101865 |
Completed |
The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01) |
|
|
Interventional
|
Not Applicable |
- University of Cambridge
- European Commission
- Medtronic
- (and 8 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl)
- Time spent below target glucose (3.9mmol/l)(70mg/dl)
- Time spent above target glucose (10.0mmol/l) (180mg/dl)
- (and 10 more...)
|
24 |
All |
1 Year to 7 Years (Child) |
NCT03101865 |
KidsAP01 |
|
August 8, 2017 |
May 11, 2018 |
May 11, 2018 |
April 5, 2017 |
June 5, 2018 |
|
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz
Graz, Austria - Department of Pediatrics I, Medical University of Innsbruck
Innsbruck, Austria - Deptartment of Pediatrics, Medical University of Vienna
Vienna, Austria - (and 4 more...)
|
|
| 45 |
NCT03732859 |
Recruiting |
PROOF-Registry New and Extended Belgium -Luxembourg |
- Idiopathic Pulmonary Fibrosis
|
|
Observational
|
|
- Belgian Thoracic Society
- Boehringer Ingelheim
- Roche Farma, S.A
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The first occurrence of a decrease of ≥ 10% in percent predicted forced vital capacity (FVC) since baseline.
- The first occurrence of a decrease of ≥ 15% in percent predicted diffusing capacity of the lung for carbon monoxide (DLCO) since baseline
- Number of participants alive
- (and 17 more...)
|
600 |
All |
19 Years and older (Adult, Older Adult) |
NCT03732859 |
BVPSBP01 |
PROOF-NEXT |
January 9, 2018 |
January 9, 2021 |
January 9, 2023 |
November 7, 2018 |
November 7, 2018 |
|
- Ziekenhuisnetwerk Antwerpen vzw
Antwerp, Belgium - Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium - Cliniques universitaires Saint-Luc
Brussels, Belgium - (and 6 more...)
|
|
| 46 |
NCT03475238 |
Recruiting |
Analysis of Factors Related to Occurrence of Serious Adverse Events During Nursing in Intensive Care Units |
- Nursing Caries
- Critical Care
|
|
Observational
|
|
- French Society for Intensive Care
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of occurrence of at least one serious avderse event (SAE) (defined below) during the nursing care while the study period (72 hours)
|
200 |
All |
Child, Adult, Older Adult |
NCT03475238 |
2018-A00046-49 |
NURSIE |
March 29, 2018 |
July 15, 2018 |
October 1, 2018 |
March 23, 2018 |
August 3, 2018 |
|
- Hopital de Bruxelles
Bruxelles, Belgium - CHU Charleroi
Charleroi, Belgium - CHU Charleroi
Charleroi, Belgium - (and 26 more...)
|
|
| 47 |
NCT03052309 |
Recruiting |
BIOLUX P-III BENELUX All-Comers Registry |
- Peripheral Arterial Disease
|
- Device: Passeo-18 Lux DCB
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Freedom from Major Adverse Events (MAE)
- Freedom from clinically driven target lesion revascularization (cd-TLR)
- Freedom from clinically-driven target lesion revascularization (cd-TLR)
- (and 10 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03052309 |
C1604 |
|
February 27, 2017 |
February 2019 |
February 2020 |
February 14, 2017 |
September 27, 2017 |
|
- Ziekenhuis Oost Limburg Genk
Genk, Belgium - University Hospital Gent (UZ Gent)
Gent, Belgium - Algemeen Ziekenhuis Groeninge Kortrijk
Kortrijk, Belgium - (and 6 more...)
|
|
| 48 |
NCT03289273 |
Recruiting |
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC) |
|
- Drug: Regorafenib (Stivarga, BAY73-4506)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)
- Overall survival (OS)
- Progression-free survival (PFS)
- (and 3 more...)
|
1000 |
All |
Child, Adult, Older Adult |
NCT03289273 |
19244
EUPAS20981 |
|
September 13, 2017 |
July 30, 2022 |
October 1, 2022 |
September 20, 2017 |
January 15, 2019 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - St. Joseph´s Hospital and Medical Center
Phoenix, Arizona, United States - University of Florida Health
Gainesville, Florida, United States - (and 41 more...)
|
|
| 49 |
NCT03249584 |
Recruiting |
OsteoCool Tumor Ablation Post-Market Study |
- Metastasis Spine
- Metastasis to Bone
|
- Device: OsteoCool™ RF Ablation
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement of worst pain score
- Change in worst pain score
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT03249584 |
MDT16075 |
OPuS One |
October 12, 2017 |
April 2019 |
November 2021 |
August 15, 2017 |
January 18, 2019 |
|
- Banner - University Medical Center Phoenix
Phoenix, Arizona, United States - Saint Jude Medical Center
Fullerton, California, United States - Moffitt Cancer Center
Tampa, Florida, United States - (and 12 more...)
|
|
| 50 |
NCT03191786 |
Recruiting |
A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy |
- Non-Small Cell Lung Cancer
|
- Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Drug: Vinorelbine
- Drug: Gemcitabine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Percentage of Participants Who Are Alive at Specified Timepoints
- Percentage of Participants With Objective Response, as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (v1.1)
- (and 7 more...)
|
441 |
All |
18 Years and older (Adult, Older Adult) |
NCT03191786 |
MO29872
2015-004105-16 |
IPSOS |
September 11, 2017 |
January 20, 2021 |
January 20, 2021 |
June 19, 2017 |
January 15, 2019 |
|
- Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina - Hospital Privado de Comunidad
Mar del Plata, Argentina - Centro de Investigacion; Clinica - Clinica Viedma S.A.
Viedma, Argentina - (and 101 more...)
|
|
| 51 |
NCT02907463 |
Completed |
EDWARDS INTUITY Elite Valve System |
- Aortic Valve Disease
- Aortic Stenosis
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Other
|
- Cross Clamp Time
- Operative Adverse Events
|
273 |
All |
18 Years and older (Adult, Older Adult) |
NCT02907463 |
2015-05 |
MISSION |
February 2016 |
April 2017 |
December 2017 |
September 20, 2016 |
March 1, 2018 |
|
- Universitätsklinik für Herzchirurgie Medizinische Universität Innsbruck
Innsbruck, Austria - Klinisshe Abteiluing Für Herz-thoraxchirurgie
Vienna, Austria - Aarhus Universitets Hospital Skejby
Aarhus N, Denmark - (and 20 more...)
|
|
| 52 |
NCT02830477 |
Recruiting |
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis |
|
- Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Proportion of patients on 2x weekly prophylaxis
- Proportion of patients on 3x weekly prophylaxis
- Composite number of reported bleeds (total, spontaneous, joint and trauma)
- (and 8 more...)
|
350 |
Male |
Child, Adult, Older Adult |
NCT02830477 |
18559
KV1601 |
TAURUS |
October 14, 2016 |
December 31, 2021 |
June 30, 2022 |
July 13, 2016 |
December 25, 2018 |
|
- Children's Rehabilitation Services/ University of South Alabama
Mobile, Alabama, United States - University of Colorado Hemophilia and Thrombosis Center
Aurora, Colorado, United States - University of Florida Health Cancer Center
Gainesville, Florida, United States - (and 24 more...)
|
|
| 53 |
NCT02785900 |
Terminated
Has Results |
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: 33A
- Drug: placebo
- Drug: azacitidine
- Drug: decitabine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Survival
- Composite Complete Remission (CRc) Rate
- Minimal Residual Disease (MRD)-Negative Composite Complete Remission Rate
- (and 7 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT02785900 |
SGN33A-005
2015-003482-28 |
CASCADE |
May 2016 |
October 3, 2017 |
October 3, 2017 |
May 30, 2016 |
December 12, 2018 |
December 12, 2018 |
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - City of Hope National Medical Center
Duarte, California, United States - Pacific Hematology Oncology Associates
San Francisco, California, United States - (and 125 more...)
|
|
| 54 |
NCT02737501 |
Active, not recruiting |
ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants |
- Non-small Cell Lung Cancer
- Lung Cancer
- Advanced Malignancies
- Carcinoma
|
- Drug: Brigatinib
- Drug: Crizotinib
|
Interventional
|
Phase 3 |
- Ariad Pharmaceuticals
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
- Objective Response Rate (ORR)
- Intracranial ORR
- (and 7 more...)
|
275 |
All |
18 Years and older (Adult, Older Adult) |
NCT02737501 |
AP26113-13-301
U1111-1210-4363 |
ALTA-1L |
May 26, 2016 |
July 31, 2020 |
July 31, 2020 |
April 14, 2016 |
August 23, 2018 |
|
- USOR - Arizona Oncology Associates - Sedona
Sedona, Arizona, United States - Kaiser Permanente Bellflower Medical Offices
Bellflower, California, United States - University of Colorado Cancer Center
Aurora, Colorado, United States - (and 88 more...)
|
|
| 55 |
NCT02699736 |
Enrolling by invitation |
Clinical and Virological Outcome of European Patients Infected With HIV |
- HIV
- Hepatitis B
- Hepatitis C
- (and 10 more...)
|
|
Observational
|
|
- Rigshospitalet, Denmark
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes
- Number of patients experiencing HIV-related events over time
- Number of participants experiencing HIV-related events by region
- (and 7 more...)
|
20852 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT02699736 |
The EuroSIDA Study
QLK2-2000-00773
LSHC-CT-2006-018632
Gilead EuroSIDA
GSK EuroSIDA
Janssen EuroSIDA
CT94-1637
CT97-2713
Pfizer EuroSIDA
Merck EuroSIDA
BMS EuroSIDA
SNSF 108787 |
EuroSIDA |
January 1994 |
December 2030 |
December 2030 |
March 4, 2016 |
April 27, 2018 |
|
- Hospital JM Ramos Mejia
Buenos Aires, Argentina - Medical University Insbruck
Innsbruck, Austria - Otto Wagner Spital
Vienna, Austria - (and 107 more...)
|
|
| 56 |
NCT02671422 |
Active, not recruiting |
LUME BioNIS: a Biomarker Study in Patients With NSCLC |
- Carcinoma, Non-Small-Cell Lung
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall Survival
- Disease progression
|
380 |
All |
18 Years and older (Adult, Older Adult) |
NCT02671422 |
1199.223 |
|
March 9, 2016 |
June 30, 2019 |
June 30, 2019 |
February 2, 2016 |
December 11, 2018 |
|
- LK Krems
Krems, Austria - AKH - Medical University of Vienna
Wien, Austria - Brussels - UNIV Saint-Luc
Bruxelles, Belgium - (and 78 more...)
|
|
| 57 |
NCT02607878 |
Completed |
Automated Pupillometry for Coma Prognostication After Cardiac Arrest |
|
|
Observational
|
|
- Centre Hospitalier Universitaire Vaudois
- Erasme University Hospital
- Azienda Ospedaliera San Gerardo di Monza
- (and 7 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
470 |
All |
18 Years and older (Adult, Older Adult) |
NCT02607878 |
432/14 |
|
January 2015 |
March 2017 |
July 2017 |
November 18, 2015 |
April 2, 2018 |
|
- Erasme University Hospital
Brussels, Belgium - University Hospital, Grenoble
Grenoble, France - Cochin Hospital
Paris, France - (and 7 more...)
|
|
| 58 |
NCT02588144 |
Recruiting |
Combined Stimulation of STN and SNr for Resistant Freezing of Gait in Parkinson's Disease |
|
- Procedure: [standard STN]
- Procedure: [STN+SNr]
|
Interventional
|
Not Applicable |
- University Hospital Tuebingen
- Medtronic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Freezing of Gait Assessment Course (FOG-AC)
- Timed Walking test from Core Assessment Program for Surgical Interventions in Parkinson's disease (CAPSIT-PD)
- Berg Balance Scale
- (and 9 more...)
|
54 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02588144 |
IHanci |
STN+SNr |
October 2015 |
September 2017 |
September 2017 |
October 27, 2015 |
June 20, 2017 |
|
- Center of Neurology and Hertie Institute for Clinical Brain Research, Department for Neurodegenerative Diseases and Neurosurgery University of Tübingen
Tübingen, Baden-Württemberg, Germany - Ludwig-Maximilians-University Munich, Klinikum Großhadern, Department for Neurology and Neurosurgery
Munich, Bayern, Germany - University Hospital Regensburg , Department for Neurology and Neurosurgery
Regensburg, Bayern, Germany - (and 7 more...)
|
|
| 59 |
NCT02552940 |
Completed |
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice |
|
|
Observational
|
|
- Hoffmann-La Roche
- nv Roche sa
|
Industry / Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Correlation coefficient between DAS28 - erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAl)
- Correlation Coefficient Between CDAI and simplified disease activity index (SDAI) and Between SDAI and DAS28-ESR
- Percentage of participants to achieve low disease activity (LDA) using DAS28 (less than or equal to [<=] 3.2), CDAl (<=10.0) and SDAI (<=11 .0)
- (and 20 more...)
|
140 |
All |
18 Years and older (Adult, Older Adult) |
NCT02552940 |
ML29691 |
|
October 31, 2015 |
October 23, 2017 |
October 23, 2017 |
September 17, 2015 |
May 11, 2018 |
|
- ASZ Aalst
Aalst, Belgium - AZ Sint Lucas Brugge
Assebroek, Belgium - AZ Sint Jan
Brugge, Belgium - (and 19 more...)
|
|
| 60 |
NCT02495051 |
Completed |
Esophageal Atresia: Metaplasia, Barrett |
- Gastroesophageal Reflux
- Esophagus, Barrett
|
- Procedure: esophageal biopsies
|
Observational
|
|
- University Hospital, Lille
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- presence of gastric and / or intestinal metaplasia diagnosed at histology
- presence of esophagitis or anomalies at the anastomotic stage diagnosed at histology
- evaluation of the nutritional status
- (and 2 more...)
|
120 |
All |
15 Years to 19 Years (Child, Adult) |
NCT02495051 |
2009/cic
DR-2011-057 / A 910270 |
Oesophagix |
February 2010 |
March 2013 |
March 2013 |
July 13, 2015 |
July 13, 2015 |
|
- Cliniques Universitaires St Luc,
Bruxelles, Belgium - Department of Pediatric Gastroenterology, AZ VUB,
Bruxelles, Belgium - Department of Pediatric Gastroenterology, HUDERF,
Bruxelles, Belgium - (and 17 more...)
|
|
| 61 |
NCT02326337 |
Active, not recruiting |
Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers |
|
- Device: TWO2 Device
- Device: Placebo Device
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Wound closure within 12 weeks with the use of Topical Wound Oxygen Therapy (TWO2)
- Time to complete wound closure
- Change in wound size over time
- (and 5 more...)
|
73 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT02326337 |
AOTI- TWO2DFU-01 |
TWO2DFU |
October 2014 |
February 5, 2018 |
December 15, 2018 |
December 29, 2014 |
February 22, 2018 |
|
- Carl T. Hayden VA Medical Center
Phoenix, Arizona, United States - NorthBay Center for Wounds
Vacaville, California, United States - Washington DC VA Medical Center
Washington, District of Columbia, United States - (and 14 more...)
|
|
| 62 |
NCT02282176 |
Withdrawn |
TINN2: Treat Infection in NeoNates 2 |
- Bronchopulmonary Dysplasia
|
- Drug: Azithromycin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Institut National de la Santé Et de la Recherche Médicale, France
- Inserm-Transfert (IT)
- University of Liverpool
- (and 13 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The proportion of surviving infants without CLD (Chronic Lung Disease) in the azithromycin treatment group when compared to placebo at 36 weeks post-menstrual age.
- Mortality rate (at 28 days, 36 weeks PMA, 2 years)
- Severity of CLD (Chronic Lung Disease) according to NIH definition
- (and 13 more...)
|
0 |
All |
23 Weeks to 28 Weeks (Child) |
NCT02282176 |
C12-75
2013-003889-14 |
TINN2 |
January 2015 |
January 2017 |
January 2018 |
November 4, 2014 |
February 25, 2016 |
|
- Centre Hospitalier Chrétien (CHC)
Liège, Belgium - Assistance Publique Hôpitaux de Paris (APHP)
Paris, France - Inserm-Transfert (IT)
Paris, France - (and 13 more...)
|
|
| 63 |
NCT02247128 |
Recruiting |
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation |
- Aortic Valve Disease
- Myocardial Infarction
- Stroke
- Bleeding
|
- Drug: Aspirin + clopidogrel
- Drug: Aspirin monotherapy
- Drug: OAC + clopicogrel
- Drug: OAC monotherapy
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Safety endpoint
- Net-clinical benefit endpoint
- Efficacy endpoint
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02247128 |
POPTAV006 |
POPular-TAVI |
January 2014 |
January 2019 |
January 2020 |
September 23, 2014 |
September 13, 2018 |
|
- Algemeen Stedelijk Ziekenhuis
Aalst, Belgium - Onze Lieve Vrouwe Ziekenhuis
Aalst, Belgium - Imelda Ziekenhuis
Bonheiden, Belgium - (and 14 more...)
|
|
| 64 |
NCT02227758 |
Completed
Has Results |
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache |
- Intractable Chronic Migraine
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Adverse Events (First 12 Weeks)
- Headache Pain Relief
- Headache Days
- (and 4 more...)
|
112 |
All |
18 Years and older (Adult, Older Adult) |
NCT02227758 |
NM-11-059-EU-ON |
Relief |
September 2012 |
December 2015 |
December 2015 |
August 28, 2014 |
December 31, 2018 |
December 31, 2018 |
- Heilig Hartziekenhuis
Roeselare, West-Vlaanderen, Belgium - Centre Hospitalier Régional de la CITADELLE
Liège, Belgium - Klinikum Delmenhorst GmbH
Delmenhorst, Großherzogtum Oldenburg, Germany - (and 15 more...)
|
|
| 65 |
NCT02156804 |
Active, not recruiting |
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) |
|
- Drug: Nivolumab (BMS-936558)
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma
- Rate and frequency of AEs regardless of causality
- Rate and frequency of treatment-related AEs
- (and 6 more...)
|
1215 |
All |
18 Years and older (Adult, Older Adult) |
NCT02156804 |
CA209-172
2014-001286-28 |
|
October 7, 2014 |
January 30, 2019 |
January 30, 2019 |
June 5, 2014 |
July 13, 2018 |
|
- Local Institution
Graz, Austria - Local Institution
Innsbruck, Austria - Local Institution
Salzburg, Austria - (and 169 more...)
|
|
| 66 |
NCT02141438 |
Active, not recruiting |
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer |
- Metastatic Castration-resistant Prostate Cancer
|
- Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of developing second primary malignancies
- Incidence of treatment-emergent SAEs
- Incidence of drug-related treatment-emergent adverse events
- (and 6 more...)
|
1482 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02141438 |
16913 |
REASSURE |
August 20, 2014 |
September 30, 2023 |
December 31, 2023 |
May 19, 2014 |
December 27, 2018 |
|
- Homewood, Alabama, United States
- Anchorage, Alaska, United States
- Scottsdale, Arizona, United States
- (and 69 more...)
|
|
| 67 |
NCT02102165 |
Recruiting |
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. |
|
- Procedure: metastatic lesion biopsy
|
Interventional
|
Not Applicable |
- Breast International Group
- Breast European Adjuvant Studies Team
- Frontier Science & Technology Research Foundation, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Metastatic Breast Cancer (MBC) understanding
- Building new therapeutic hypotheses
- Patients' prognosis determination
- (and 4 more...)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02102165 |
BIG 14-01
1408-BCG
GBG 85
ICR-CTSU/2014/10050 |
AURORA |
April 2014 |
April 2019 |
January 2029 |
April 2, 2014 |
March 22, 2018 |
|
- Institut Jules Bordet
Brussels, Belgium - Cliniques Universitaires St-Luc
Brussels, Belgium - Grand Hopital Charleroi
Charleroi, Belgium - (and 57 more...)
|
|
| 68 |
NCT02092818 |
Completed |
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension |
|
- Drug: Riociguat (Adempas, BAY63-2521)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of adverse events/ serious adverse events
- All-cause mortality
- Number of adverse event (AE) and serious adverse event(SAE) in the different pulmonary hypertension(PH) indications (pulmonary arterial hypertension (PAH) chronic thromboembolic pulmonary hypertension(CTEPH)
- (and 2 more...)
|
1316 |
All |
Child, Adult, Older Adult |
NCT02092818 |
16657
AD1301 |
EXPERT |
May 31, 2014 |
March 31, 2018 |
June 29, 2018 |
March 20, 2014 |
December 5, 2018 |
|
- Multiple Locations, Argentina
- Multiple Locations, Australia
- Multiple Locations, Austria
- (and 25 more...)
|
|
| 69 |
NCT02042144 |
Completed |
Safety and Effectiveness of Regorafenib |
|
- Drug: Stivarga (Regorafenib, BAY73-4506)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3
- Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause.
- Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first.
- (and 3 more...)
|
1034 |
All |
18 Years and older (Adult, Older Adult) |
NCT02042144 |
16821
SV1302 |
Correlate |
April 8, 2014 |
August 19, 2017 |
November 10, 2017 |
January 22, 2014 |
January 16, 2018 |
|
- Multiple Locations, Argentina
- Multiple Locations, Austria
- Multiple Locations, Czechia
- (and 10 more...)
|
|
| 70 |
NCT02031471 |
Completed
Has Results |
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)
- Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)
- Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores
- (and 24 more...)
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT02031471 |
ML28701 |
|
January 2014 |
September 2015 |
September 2015 |
January 9, 2014 |
August 1, 2017 |
January 4, 2017 |
- Aalst, Belgium
- Assebroek, Belgium
- Bonheiden, Belgium
- (and 14 more...)
|
|
| 71 |
NCT02018744 |
Active, not recruiting |
Nellix® Registry Study: EVAS-Global |
- Safety and Performance of the Nellix Endovascular Sealing System
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Immediate procedural technical success
- Peri-operative Safety Parameters
- Clinical outcome
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02018744 |
CP0010-Ver. 1 |
EVAS-FORWARD 1 |
October 2013 |
September 2014 |
September 2019 |
December 23, 2013 |
July 30, 2018 |
|
- Klinikum Augsburg Klinik für Gefäßchirurgie
Augsburg, Germany - Universitätsklinikum Düsseldorf Klinik für Gefäß- und Endovaskularchirurgie
Düsseldorf, Germany - Alfried Krupp Krankenhaus Ruttenscheid, Vascular Centre
Essen, Germany - (and 16 more...)
|
|
| 72 |
NCT01945762 |
Recruiting |
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer |
- Symptomatic, Aggressive, Sporadic, Unresectable, Locally
- Advanced/Metastatic Medullary Thyroid Cancer (MTC)
|
|
Observational
|
|
- Genzyme, a Sanofi Company
- Worldwide Clinical Trials
- Sanofi
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessment of Objective Response Rate
- Assessment of Disease control rate
- Assessment of Duration of Response
- (and 6 more...)
|
80 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01945762 |
D4200C00104
OBS14778 |
Caprelsa104 |
February 2014 |
September 2019 |
September 2019 |
September 19, 2013 |
July 11, 2018 |
|
- Research Site
Brussels, Belgium - Research Site
Bordeaux, France - Research Site
Lyon, France - (and 27 more...)
|
|
| 73 |
NCT01856101 |
Terminated |
Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy |
- Carcinoma Transitional Cell
|
|
Interventional
|
Phase 2 |
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the efficacy of BEZ235 in patients with palliative TCC
- Determine the safety profile of BEZ235 in patients with advanced TCC
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT01856101 |
UCL-ONCO2012-01
2012-004123-20 |
BEZ235 |
February 2013 |
January 2014 |
January 2014 |
May 17, 2013 |
May 14, 2014 |
|
- Clinique Saint-Pierre à Ottignies
Ottignies, Brabant Wallon, Belgium - Epicura- RHMS Baudour
Baudour, Hainaut, Belgium - Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium - (and 9 more...)
|
|
| 74 |
NCT01849874 |
Active, not recruiting |
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer |
- Low-grade Serous Ovarian Cancer
- Low-grade Serous Fallopian Tube Cancer
- Low-grade Serous Peritoneal Cancer
|
- Drug: MEK162, MEK inhibitor; oral
- Drug: Physician's choice chemotherapy
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Demonstrate superior efficacy of study drug vs. physician's choice of selected chemotherapies in terms of increased progression-free survival.
- Obtain additional estimates of the efficacy of study drug vs. physician's choice of selected chemotherapies in terms of overall survival, objective response rate, duration of response and disease control rate.
- Characterize the safety profile of the study drug vs. physician's choice of selected chemotherapies in terms of adverse events and clinical laboratory tests.
- (and 2 more...)
|
360 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01849874 |
ARRAY-162-311
2013-000277-72 |
|
June 2013 |
April 1, 2016 |
September 2019 |
May 9, 2013 |
January 11, 2019 |
|
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Irvine, California, United States
- (and 153 more...)
|
|
| 75 |
NCT01801111 |
Completed
Has Results |
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment |
- Non-Small-Cell Lung Carcinoma
|
- Drug: Erlotinib
- Drug: Alectinib
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended Phase 2 Dose (RP2D) of Alectinib
- Percentage of Participants With Dose Limiting Toxicities (DLTs)
- Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population
- (and 33 more...)
|
138 |
All |
18 Years and older (Adult, Older Adult) |
NCT01801111 |
NP28673
2012-004455-36 |
|
June 20, 2013 |
October 24, 2014 |
October 27, 2017 |
February 28, 2013 |
November 2, 2018 |
May 26, 2016 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - St. Jude Heritage Healthcare
Fullerton, California, United States - UC Irvine Medical Center
Orange, California, United States - (and 81 more...)
|
|
| 76 |
NCT01702571 |
Active, not recruiting |
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment |
|
- Drug: Trastuzumab Emtansine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment
- Overall Survival According to RECIST v 1.1 As Per Investigator Assessment
- (and 4 more...)
|
2003 |
All |
18 Years and older (Adult, Older Adult) |
NCT01702571 |
MO28231
2012-001628-37 |
|
November 27, 2012 |
October 21, 2016 |
September 30, 2019 |
October 8, 2012 |
September 11, 2017 |
|
- CEMIC
Buenos Aires, Argentina - Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina - Hospital Privado De Comunidad; General Practice
Mar Del Plata, Argentina - (and 303 more...)
|
|
| 77 |
NCT01667458 |
Completed |
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evolution of fatigue: Proportion of patients meeting the Minimally Clinically Important Difference (MCID) for the Visual Analogue Sale VAS Fatigue at Week 16
- Fatigue: VAS Fatigue/FACIT Fatigue/Pass Fatigue
- Disease Activity Score DAS28
- (and 5 more...)
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT01667458 |
ML25702 |
|
September 2011 |
December 2012 |
December 2012 |
August 17, 2012 |
November 2, 2016 |
|
- Aalst, Belgium
- Assebroek, Belgium
- Ath, Belgium
- (and 15 more...)
|
|
| 78 |
NCT01528163 |
Completed |
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
- Squamous Cell Carcinoma of the Head and Neck
|
- Drug: Cabazitaxel
- Drug: Methotrexate
|
Interventional
|
Phase 2 |
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
101 |
All |
18 Years and older (Adult, Older Adult) |
NCT01528163 |
UCL-ONCO 2011-01
2011-001938-42 |
RACATREX |
February 2012 |
November 2014 |
November 2014 |
February 7, 2012 |
June 14, 2017 |
|
- Clinique Saint-Pierre
Ottignies, Brabant Wallon, Belgium - Cliniques universitaires Saint-Luc, Centre du Cancer, Oncologie Médicale
Brussels, Bruxelles Capitale, Belgium - RHMS Baudour
Baudour, Hainaut, Belgium - (and 13 more...)
|
|
| 79 |
NCT01520506 |
Completed
Has Results |
Rapid Renal Sympathetic Denervation for Resistant Hypertension |
- Hypertension, Resistant to Conventional Therapy
|
- Device: Covidien OneShot™ System
|
Interventional
|
Phase 2 |
- Medtronic Endovascular
- Medtronic - MITG
- Meditrial Europe Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acute Procedural Safety
- Chronic Procedural Safety
- Renal Denervation Procedure Effectiveness
|
50 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01520506 |
CIP 012 |
RAPID |
May 2012 |
November 2013 |
June 2014 |
January 30, 2012 |
September 16, 2015 |
September 16, 2015 |
- Middelheim Hospital
Antwerp, Belgium - Ziekenhuis Oost--Limburg
Genk, Belgium - Universitatklinikum
Bonn, Germany - (and 11 more...)
|
|
| 80 |
NCT01508286 |
No longer available |
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects |
|
- Drug: Telaprevir + peginterferon alfa + ribavirin
- Drug: peginterferon alfa + ribavirin
|
Expanded Access
|
|
- Janssen-Cilag International NV
|
Industry |
|
|
|
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01508286 |
CR017857
VX-950HEP3002
2010-023669-23 |
|
|
|
|
January 11, 2012 |
July 24, 2015 |
|
- Adelaide, Australia
- Bedford, Australia
- Box Hill, Australia
- (and 131 more...)
|
|
| 81 |
NCT01500616 |
Completed |
Telaprevir Open-Label Study in Co-Infected Patients |
|
|
Interventional
|
Phase 3 |
- Janssen-Cilag International NV
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment-emergent Adverse Events
|
122 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01500616 |
CR018787
VX-950HPC3005
2011-003593-85 |
|
June 2012 |
August 2014 |
August 2014 |
December 28, 2011 |
August 18, 2016 |
|
- Antwerpen, Belgium
- Brussel, Belgium
- Bruxelles, Belgium
- (and 29 more...)
|
|
| 82 |
NCT01475799 |
Active, not recruiting |
Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis |
|
- Device: Replacement of the Aortic Stenotic Valve
|
Interventional
|
Not Applicable |
- Direct Flow Medical, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Freedom from all-cause mortality from procedure to 30 days
- Device Success at procedure completion
|
112 |
All |
70 Years and older (Older Adult) |
NCT01475799 |
IP 010 |
|
November 2011 |
July 2014 |
July 2019 |
November 21, 2011 |
November 1, 2016 |
|
- L'Institut Hospitalier Jacques Cartier
Massy, France - Clinique Pasteur
Toulouse, France - Vivantes Klinikum im Friedrichshain
Berlin, DE, Germany - (and 9 more...)
|
|
| 83 |
NCT01346709 |
Completed |
Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe |
- Complication of Surgical Procedure
- Acute Respiratory Failure, Adult
- Postoperative Respiratory Complications
- (and 2 more...)
|
|
Observational
|
|
- European Society of Anaesthesiology
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The main outcome, defined as a postoperative pulmonary complications (PPC), will be a composite of the in-hospital fatal or non-fatal postoperative events.
- a) Postoperative length of stay
- b) In-hospital mortality
|
5183 |
All |
18 Years and older (Adult, Older Adult) |
NCT01346709 |
PERISCOPE |
PERISCOPE |
May 2011 |
August 2011 |
September 2011 |
May 3, 2011 |
March 5, 2014 |
|
- University Hospital centre "Mother Theresa" Anesthesia & critical Care
Tirana, Albania - Cliniques Universitaires Saint Luc
Brussels, Belgium - General Hospital "Prim.dr Abdulah Nakas" Departement of Anaesthesia and intensive care
Sarajevo, Bosnia and Herzegovina - (and 60 more...)
|
|
| 84 |
NCT01308021 |
Completed |
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis |
- Grass Pollen Allergy
- Hay Fever
|
- Biological: gpASIT+TM
- Biological: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Impact of gpASIT+TM on the clinical efficacy of the subjects
- Clinical tolerability and safety of the treatment
- Impact of gpASIT+TM on the immunological status of the subjects
- (and 2 more...)
|
202 |
All |
18 Years to 50 Years (Adult) |
NCT01308021 |
BTT-gpASIT005 |
|
December 2010 |
October 2011 |
December 2011 |
March 3, 2011 |
May 26, 2014 |
|
- CHR Saint Joseph Warquignies
Boussu, Belgium - AZ Sint Lucas
Brugge, Belgium - Clinique du Parc Léopold
Brussels, Belgium - (and 16 more...)
|
|
| 85 |
NCT01268514 |
Active, not recruiting |
ENHANCE: A Prospective EvaluatioN of Permacol™ in tHe Repair of Complex AbdomiNal Wall CasEs |
- Hernia, Abdominal
- Abdominal Injuries
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Hernia Recurrence
- Short-term and mid-term outcomes
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT01268514 |
COVPERH0108 |
ENHANCE |
February 2011 |
March 2017 |
April 2017 |
December 31, 2010 |
February 14, 2017 |
|
- AZ St.-Jan AV
Brugge, Belgium - AZ St Lucas
Gent, Belgium - CHU Ambroise Paré
Mons, Belgium - (and 9 more...)
|
|
| 86 |
NCT01254279 |
Completed |
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen |
- Prostate Cancer Metastatic
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen
- To document safety of cabazitaxel in these patients
|
984 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01254279 |
CABAZ_C_05331
2010-021128-92
U1111-1115-2476 |
|
December 2010 |
December 2014 |
December 2014 |
December 6, 2010 |
January 21, 2015 |
|
- Investigational Site Number 036004
Box Hill, Australia - Investigational Site Number 036020
Campbelltown, Australia - Investigational Site Number 036001
Camperdown, Australia - (and 162 more...)
|
|
| 87 |
NCT01235962 |
Active, not recruiting |
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) |
|
- Drug: pazopanib
- Drug: placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
- Disease-free survival rates at yearly time points (e.g. 1 year, 2 years, etc.).
- (and 2 more...)
|
1536 |
All |
18 Years and older (Adult, Older Adult) |
NCT01235962 |
113387 |
PROTECT |
December 1, 2010 |
October 15, 2015 |
April 15, 2019 |
November 8, 2010 |
October 12, 2018 |
|
- Novartis Investigative Site
Jonesboro, Arkansas, United States - Novartis Investigative Site
Antioch, California, United States - Novartis Investigative Site
Beverly Hills, California, United States - (and 313 more...)
|
|
| 88 |
NCT00598663 |
Completed |
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c |
- Diabetes Mellitus, Type 1
|
- Device: insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)
- Device: insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- HbA1c
- Change in glycemic variability
- Change in occurrence of hypoglycemia
- (and 4 more...)
|
154 |
All |
6 Years to 70 Years (Child, Adult, Older Adult) |
NCT00598663 |
EUR03
ISRCTN09806152 |
SWITCH |
January 2008 |
July 2010 |
July 2010 |
January 22, 2008 |
September 20, 2010 |
|
- Hospital Hietzing
Vienna, Austria - Steno Diabetes Center
Copenhagen, Denmark - Glostrup Hospital
Glostrup, Denmark - (and 5 more...)
|
|
| 89 |
NCT01171404 |
Completed |
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge |
- ACS
- Acute Coronary Syndrome
- Myocardial Infarction
- (and 2 more...)
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Clinical outcomes (ischemic and bleeding) incidence and time to these clinical outcomes
- Antithrombotic treatments
- Use of health care resources
- Quality of life
|
10568 |
All |
18 Years and older (Adult, Older Adult) |
NCT01171404 |
NIS-CEU-DUM-2009/1 |
EPICOR |
September 2010 |
March 2013 |
March 2013 |
July 28, 2010 |
April 17, 2013 |
|
- Research Site
Avellaneda, Argentina - Research Site
Bahia Blanca, Argentina - Research Site
Ciudad Autonoma de Buenos Aires, Argentina - (and 408 more...)
|
|
| 90 |
NCT01154140 |
Completed
Has Results |
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) Based on IRR
- Overall Survival (OS)
- Overall Survival Probability at Month 12 and 18
- (and 21 more...)
|
343 |
All |
18 Years and older (Adult, Older Adult) |
NCT01154140 |
A8081014
2010-021336-33
XALCORI |
PROFILE 1014 |
January 13, 2011 |
November 30, 2013 |
November 30, 2016 |
June 30, 2010 |
November 6, 2017 |
January 5, 2015 |
- Tower Cancer Research Foundation
Beverly Hills, California, United States - Tower Hematology Oncology Medical Group
Beverly Hills, California, United States - CCTAP
Fontana, California, United States - (and 246 more...)
|
|
| 91 |
NCT00917046 |
Completed |
The SMARTEX Heart Failure Study |
|
- Behavioral: high-intensity interval training
- Behavioral: Moderate continuous training
- Behavioral: Recommendation of regular moderate exercise
|
Interventional
|
Not Applicable |
- Norwegian University of Science and Technology
- University Hospital, Antwerp
- UMC Utrecht
- (and 9 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks
- Exercise capacity
- quality of life
- (and 3 more...)
|
261 |
All |
18 Years and older (Adult, Older Adult) |
NCT00917046 |
090309 |
SMARTEX |
January 2009 |
September 2013 |
July 2014 |
June 10, 2009 |
January 18, 2017 |
|
- University Hospital Antwerp
Antwerp, Belgium - Bispebjerg University Hospital
Copenhagen, Denmark - Universitaet Leipzig, Herzzentrum GmbH
Leipzig, Germany - (and 8 more...)
|
|
| 92 |
NCT01082549 |
Completed |
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) |
- Squamous Cell Lung Cancer
|
- Drug: gemcitabine/carboplatin
- Drug: gemcitabine/carboplatin plus Iniparib
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- progression free survival
|
780 |
All |
18 Years and older (Adult, Older Adult) |
NCT01082549 |
EFC11553
20090321 |
ECLIPSE |
March 2010 |
April 2013 |
April 2013 |
March 8, 2010 |
March 17, 2016 |
|
- Investigational Site Number 840306
Birmingham, Alabama, United States - Investigational Site Number 840207
Huntsville, Alabama, United States - Investigational Site Number 840351
Muscle Shoals, Alabama, United States - (and 139 more...)
|
|
| 93 |
NCT01032629 |
Completed
Has Results |
CANVAS - CANagliflozin cardioVascular Assessment Study |
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Risk Factors
|
- Drug: Placebo
- Drug: Canagliflozin (JNJ-28431754) 100 mg
- Drug: Canagliflozin (JNJ-28431754) 300 mg
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
- The George Institute for Global Health, Australia
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke
- Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)
- Percentage of Participants With Progression of Albuminuria at the End-of-Treatment
- (and 10 more...)
|
4330 |
All |
30 Years and older (Adult, Older Adult) |
NCT01032629 |
CR016627
28431754DIA3008
2009-012140-16 |
CANVAS |
December 9, 2009 |
February 22, 2017 |
February 22, 2017 |
December 15, 2009 |
December 7, 2018 |
December 7, 2018 |
- Birmingham, Alabama, United States
- Mesa, Arizona, United States
- Tucson, Arizona, United States
- (and 310 more...)
|
|
| 94 |
NCT01020916 |
Completed |
Target Temperature Management After Cardiac Arrest |
- Out-of-hospital Cardiac Arrest
|
- Procedure: Target temperature 36°C
- Procedure: Target Temperature 33°C
|
Interventional
|
Not Applicable |
- Niklas Nielsen
- Scandinavian Critical Care Trials Group
- Copenhagen Trial Unit, Center for Clinical Intervention Research
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause mortality
- Composite outcome of all-cause mortality and poor neurological function (CPC 3 and 4) and composite outcome of all-cause mortality and poor neurological function (modified Rankin Scale 4 and 5)
- Bleeding
- (and 10 more...)
|
950 |
All |
18 Years and older (Adult, Older Adult) |
NCT01020916 |
TTM-1 |
TTM |
November 2010 |
July 2013 |
July 2013 |
November 26, 2009 |
July 10, 2013 |
|
- Liverpool Hospital
Sydney, Australia - North Shore Hospital
Sydney, Australia - St George Hospital
Sydney, Australia - (and 30 more...)
|
|
| 95 |
NCT00976638 |
Completed |
Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares |
- Hospital Acquired Infections
|
- Other: Chromogenic surveillance
- Other: Molecular surveillance
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Colonization with MRSA, VRE and ESBL
- Incidence density of new acquisitions with MRSA, VRE and ESBL individually.
- ICU-acquired bacteremia rates with MRSA,VRE or ESBL.
- 28 day-mortality
|
14318 |
All |
18 Years and older (Adult, Older Adult) |
NCT00976638 |
LSHP-CT-2007-037941
WP3 |
MOSAR-ICU |
June 2008 |
May 2011 |
May 2011 |
September 14, 2009 |
August 6, 2012 |
|
- Hopital Henri Mondor
Creteil, France - Raymond Poincare Hospital
Garches, France - Hopital Paris Saint Joseph
Paris, France - (and 10 more...)
|
|
| 96 |
NCT00960128 |
Completed |
Observational Prospective Study on Patients Treated With Norditropin® |
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Adult Growth Hormone Deficiency
- (and 7 more...)
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Effect of Norditropin® treatment on height gain (change in height) in children
- Effect of Norditropin® treatment on body weight and body composition in adults
- Effect of Norditropin® treatment body weight, blood biochemistry, bone age, the endocrine system and pubertal development in children
- Effect of Norditropin® treatment on quality of life, blood biochemistry and the endocrine system in adults
|
21249 |
All |
Child, Adult, Older Adult |
NCT00960128 |
GHLIQUID-3676
2008-001674-32 |
|
April 1, 2006 |
December 31, 2016 |
December 31, 2016 |
August 17, 2009 |
October 12, 2017 |
|
- Novo Nordisk Investigational Site
Prov. de Buenos Aires, Argentina - Novo Nordisk Investigational Site
Brussels, Belgium - Novo Nordisk Investigational Site
Prague, Czechia - (and 20 more...)
|
|
| 97 |
NCT00867048 |
Active, not recruiting |
Strategic Timing of Antiretroviral Treatment |
|
- Drug: All licensed antiretroviral medications
|
Interventional
|
Phase 4 |
- University of Minnesota - Clinical and Translational Science Institute
- National Institute of Allergy and Infectious Diseases (NIAID)
- Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark
- (and 19 more...)
|
Other / NIH / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Composite endpoint of AIDS, serious non-AIDS diagnoses, and all-cause mortality
- Components of the composite primary outcome measure
- Specific non-AIDS diagnoses
- (and 9 more...)
|
4688 |
All |
18 Years and older (Adult, Older Adult) |
NCT00867048 |
0603M83587
U01AI068641
2008-006439-12 |
START |
March 2009 |
December 2021 |
December 2021 |
March 23, 2009 |
October 11, 2018 |
|
- University of Southern California
Alhambra, California, United States - VA Greater Los Angeles Healthcare System
Los Angeles, California, United States - UCLA CARE-4-Families (LABAC CRS)
Los Angeles, California, United States - (and 215 more...)
|
|
| 98 |
NCT00750880 |
Completed
Has Results |
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. |
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events (AEs): Overall Summary
- Percentage of Participants Who Achieved Low Disease Activity or Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28) by Visit
- Time to Low Disease Activity or Remission Based on DAS28 - Number of Participants With an Event
- (and 17 more...)
|
1681 |
All |
18 Years and older (Adult, Older Adult) |
NCT00750880 |
MA21573
2008-000587-17 |
|
September 2008 |
July 2011 |
July 2011 |
September 11, 2008 |
July 22, 2015 |
August 7, 2014 |
- Canberra, Australian Capital Territory, Australia
- Coffs Harbour, New South Wales, Australia
- Kogarah, New South Wales, Australia
- (and 279 more...)
|
|
| 99 |
NCT00541281 |
Completed |
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer |
- Hormone Resistant Prostate Cancer
- Metastatic Prostate Cancer
|
- Drug: docetaxel
- Drug: estramustine
- Drug: prednisone
|
Interventional
|
Phase 2 |
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Sanofi
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To compare the efficacy of the association of Docetaxel and Estramustineand Prednisone versus Docetaxel and Prednisone in the treatment of hormone refractory prostate cancer in terms o PSA response
- PSA response Time to PSA progression PSA response duration Event Progression-Free Survival Overall survival Palliative response (Pain) Safety Objective response measurable disease (RECIST)
|
150 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00541281 |
UCL-ONCO 04-001 |
|
December 2003 |
|
February 2006 |
October 10, 2007 |
October 27, 2009 |
|
- St Pierre
Ottignies, Brabant Wallon, Belgium - Notre Dame et Reine Fabiola
Charleroi, Hainaut, Belgium - RHMS louis caty
Baudour, Belgium - (and 16 more...)
|
|
| 100 |
NCT00431769 |
Completed |
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma |
|
|
Interventional
|
Phase 2 |
- Janssen-Cilag International NV
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best Confirmed Response to Bortezomib Re-Treatment
- Participants With Percent Change in Baseline Serum Monoclonal Protein (M-protein) Best Confirmed Response Category
- Participants with Percent Change in Baseline Urine Monoclonal Protein (M-protein) Best Confirmed Response Category
- (and 2 more...)
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT00431769 |
CR010519
26866138MMY2036
2005-005819-26 |
|
June 2006 |
February 2009 |
January 2010 |
February 6, 2007 |
May 12, 2014 |
|
- Graz, Austria
- Oberpullendorf, Austria
- Wien, Austria
- (and 36 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: